Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

BACKGROUND: No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab. METHODS: We performed an uncontrol...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:N Engl J Med
Auteurs principaux: Tolaney, Sara M., Barry, William T., Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth A., Partridge, Ann H., Guo, Hao, Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4313867/
https://ncbi.nlm.nih.gov/pubmed/25564897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1406281
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires